You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSildenafil
Accession NumberDB00203  (APRD00556)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionSildenfail is a vasoactive agent used to treat erectile dysfunction and reduce symptoms in patients with pulmonary arterial hypertension (PAH). Sildenafil elevates levels of the second messenger, cGMP, by inhibiting its breakdown via phosphodiesterase type 5 (PDE5). PDE5 is found in particularly high concentrations in the corpus cavernosum, erectile tissue of the penis. It is also found in the retina and vascular endothelium. Increased cGMP results in vasodilation which facilitates generation and maintenance of an erection. The vasodilatory effects of sildenafil also help reduce symptoms of PAH.
Structure
Thumb
Synonyms
1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-D)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act SildenafilTablet100 mgOralActavis Pharma Company2012-11-08Not applicableCanada
Act SildenafilTablet25 mgOralActavis Pharma Company2012-11-08Not applicableCanada
Act SildenafilTablet50 mgOralActavis Pharma Company2012-11-08Not applicableCanada
Auro-sildenafilTablet25 mgOralAuro Pharma IncNot applicableNot applicableCanada
Auro-sildenafilTablet50 mgOralAuro Pharma IncNot applicableNot applicableCanada
Auro-sildenafilTablet100 mgOralAuro Pharma IncNot applicableNot applicableCanada
Dom-sildenafilTablet25 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-sildenafilTablet50 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-sildenafilTablet100 mgOralDominion PharmacalNot applicableNot applicableCanada
Gd-sildenafilTablet100 mgOralGenmed A Division Of Pfizer Canada Inc2012-11-27Not applicableCanada
Gd-sildenafilTablet25 mgOralGenmed A Division Of Pfizer Canada Inc2012-11-272015-08-03Canada
Gd-sildenafilTablet50 mgOralGenmed A Division Of Pfizer Canada Inc2012-11-272015-08-03Canada
Ipg-sildenafilTablet25 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-sildenafilTablet50 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-sildenafilTablet100 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-sildenafilTablet50.0 mgOralJamp Pharma Corporation2014-12-05Not applicableCanada
Jamp-sildenafilTablet100.0 mgOralJamp Pharma Corporation2014-12-05Not applicableCanada
Jamp-sildenafilTablet25.0 mgOralJamp Pharma Corporation2014-12-05Not applicableCanada
M-sildenafilTablet25 mgOralMantra Pharma IncNot applicableNot applicableCanada
M-sildenafilTablet50 mgOralMantra Pharma IncNot applicableNot applicableCanada
M-sildenafilTablet100 mgOralMantra Pharma Inc2015-06-04Not applicableCanada
Mar-sildenafilTablet100.0 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-sildenafilTablet25.0 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-sildenafilTablet50.0 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mint-sildenafilTablet25 mgOralMint Pharmaceuticals Inc2013-02-15Not applicableCanada
Mint-sildenafilTablet50 mgOralMint Pharmaceuticals Inc2013-02-15Not applicableCanada
Mint-sildenafilTablet100 mgOralMint Pharmaceuticals Inc2013-02-15Not applicableCanada
Myl-sildenafilTablet25 mgOralMylan Pharmaceuticals Ulc2012-11-20Not applicableCanada
Myl-sildenafilTablet50 mgOralMylan Pharmaceuticals Ulc2012-11-20Not applicableCanada
Myl-sildenafilTablet100 mgOralMylan Pharmaceuticals Ulc2012-11-20Not applicableCanada
Mylan-sildenafilTablet25 mgOralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Mylan-sildenafilTablet50 mgOralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Mylan-sildenafilTablet100 mgOralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Pb-sildenafilTablet50.0 mgOralPb Pharma IncNot applicableNot applicableCanada
Pb-sildenafilTablet100.0 mgOralPb Pharma IncNot applicableNot applicableCanada
Pb-sildenafilTablet25.0 mgOralPb Pharma IncNot applicableNot applicableCanada
PMS-sildenafilTablet50 mgOralPharmascience Inc2012-11-14Not applicableCanada
PMS-sildenafilTablet100 mgOralPharmascience Inc2012-11-14Not applicableCanada
PMS-sildenafilTablet25 mgOralPharmascience Inc2012-11-14Not applicableCanada
PMS-sildenafil RTablet20 mgOralPharmascience Inc2014-11-14Not applicableCanada
Priva-sildenafilTablet100 mgOralPharmapar Inc2016-09-21Not applicableCanada
Priva-sildenafilTablet50 mgOralPharmapar IncNot applicableNot applicableCanada
Priva-sildenafilTablet25 mgOralPharmapar Inc2016-09-21Not applicableCanada
Ran-sildenafilTablet25 mgOralRanbaxy Pharmaceuticals Canada Inc.2012-11-21Not applicableCanada
Ran-sildenafilTablet50 mgOralRanbaxy Pharmaceuticals Canada Inc.2012-11-21Not applicableCanada
Ran-sildenafilTablet100 mgOralRanbaxy Pharmaceuticals Canada Inc.2012-11-21Not applicableCanada
Ratio-sildenafilTablet50 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ratio-sildenafilTablet100 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ratio-sildenafilTablet25 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ratio-sildenafil RTablet20 mgOralTeva Canada Limited2010-06-09Not applicableCanada
RevatioSolution0.8 mgIntravenousPfizer Canada Inc2010-08-31Not applicableCanada
RevatioInjection, solution0.8 mg/mlIntravenousPfizer Limited2005-10-28Not applicableEu
RevatioPowder, for suspension10 mg/mLOralPfizer Laboratories Div Pfizer Inc2014-06-02Not applicableUs
RevatioPowder, for suspension10 mg/mlOralPfizer Limited2005-10-28Not applicableEu
RevatioInjection, solution.8 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc2009-11-18Not applicableUs
RevatioTablet, film coated20 mgOralPfizer Limited2005-10-28Not applicableEu
RevatioTablet, film coated20 mg/1OralPfizer Laboratories Div Pfizer Inc2005-06-03Not applicableUs
RevatioTablet, film coated20 mg/1OralCardinal Health2005-06-03Not applicableUs
RevatioTablet, film coated20 mgOralPfizer Limited2005-10-28Not applicableEu
RevatioTablet20 mgOralPfizer Canada Inc2006-06-12Not applicableCanada
Riva-sildenafilTablet50 mgOralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-sildenafilTablet100 mgOralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-sildenafilTablet100 mgOralLaboratoire Riva Inc2016-05-06Not applicableCanada
Riva-sildenafilTablet25 mgOralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-sildenafilTablet25 mgOralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-sildenafilTablet50 mgOralLaboratoire Riva IncNot applicableNot applicableCanada
Sandoz SildenafilTablet50 mgOralSandoz Canada Incorporated2013-01-31Not applicableCanada
Sandoz SildenafilTablet100 mgOralSandoz Canada Incorporated2013-01-31Not applicableCanada
Sandoz SildenafilTablet25 mgOralSandoz Canada Incorporated2013-01-31Not applicableCanada
SildenafilTablet100 mgOralSivem Pharmaceuticals UlcNot applicableNot applicableCanada
SildenafilTablet50.0 mgOralJamp Pharma CorporationNot applicableNot applicableCanada
SildenafilTablet50 mgOralPharmascience Inc2013-08-05Not applicableCanada
SildenafilTablet25 mgOralPharmascience Inc2013-08-05Not applicableCanada
SildenafilTablet25 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
SildenafilTablet25 mgOralMethapharm IncNot applicableNot applicableCanada
SildenafilTablet50 mgOralPro Doc Limitee2014-10-07Not applicableCanada
SildenafilTablet100.0 mgOralJamp Pharma CorporationNot applicableNot applicableCanada
SildenafilTablet, film coated20 mg/1OralGreenstone LLC2012-09-27Not applicableUs
SildenafilTablet100 mgOralPharmascience Inc2013-08-05Not applicableCanada
SildenafilTablet50 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
SildenafilTablet50 mgOralMethapharm IncNot applicableNot applicableCanada
SildenafilTablet100 mgOralPro Doc Limitee2014-10-07Not applicableCanada
SildenafilTablet25 mgOralSivem Pharmaceuticals UlcNot applicableNot applicableCanada
SildenafilTablet50 mgOralSanis Health Inc2013-06-21Not applicableCanada
SildenafilTablet25 mgOralPro Doc LimiteeNot applicableNot applicableCanada
SildenafilTablet, film coated20 mg/1OralKAISER FOUNDATION HOSPITALS2014-09-19Not applicableUs
SildenafilTablet25.0 mgOralJamp Pharma CorporationNot applicableNot applicableCanada
SildenafilTablet, film coated20 mg/1OralPd Rx Pharmaceuticals, Inc.2012-09-27Not applicableUs
SildenafilTablet100 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
SildenafilTablet100 mgOralMethapharm IncNot applicableNot applicableCanada
SildenafilTablet50 mgOralSivem Pharmaceuticals UlcNot applicableNot applicableCanada
SildenafilTablet100 mgOralSanis Health Inc2013-06-21Not applicableCanada
Sildenafil CitrateTablet50.0 mgOralJubilant Generics LimitedNot applicableNot applicableCanada
Sildenafil CitrateTablet100.0 mgOralJubilant Generics LimitedNot applicableNot applicableCanada
Sildenafil CitrateTablet25.0 mgOralJubilant Generics LimitedNot applicableNot applicableCanada
Sildenafil RTablet20 mgOralMethapharm IncNot applicableNot applicableCanada
Sildenafil TabletsTablet25 mgOralDr Reddys Laboratories LtdNot applicableNot applicableCanada
Sildenafil TabletsTablet50 mgOralDr Reddys Laboratories LtdNot applicableNot applicableCanada
Sildenafil TabletsTablet100 mgOralDr Reddys Laboratories LtdNot applicableNot applicableCanada
Teva-sildenafilTablet25 mgOralTeva Canada Limited2012-11-08Not applicableCanada
Teva-sildenafilTablet50 mgOralTeva Canada Limited2012-11-08Not applicableCanada
Teva-sildenafilTablet100 mgOralTeva Canada Limited2012-11-08Not applicableCanada
Van-sildenafilTablet50.0 mgOralVanc Pharmaceuticals IncNot applicableNot applicableCanada
Van-sildenafilTablet100 mgOralVanc Pharmaceuticals Inc2015-07-22Not applicableCanada
Van-sildenafilTablet25.0 mgOralVanc Pharmaceuticals IncNot applicableNot applicableCanada
ViagraTablet, film coated50 mgOralPfizer Limited1998-09-14Not applicableEu
ViagraTablet, orally disintegrating50 mgOralPfizer Limited1998-09-14Not applicableEu
ViagraTablet, film coated100 mg/1OralU.S. Pharmaceuticals1998-03-27Not applicableUs
ViagraTablet, film coated50 mg/1OralRebel Distributors Corp2003-07-17Not applicableUs
ViagraTablet, film coated50 mgOralPfizer Limited1998-09-14Not applicableEu
ViagraTablet, film coated100 mg/1OralPhysicians Total Care, Inc.1998-03-27Not applicableUs
ViagraTablet, film coated100 mg/1OralCardinal Health1998-03-27Not applicableUs
ViagraTablet, film coated25 mg/1OralAphena Pharma Solutions Tennessee, Llc1998-03-27Not applicableUs
ViagraTablet, film coated100 mgOralPfizer Limited1998-09-14Not applicableEu
ViagraTablet, film coated100 mg/1OralAphena Pharma Solutions Tennessee, Llc1998-03-27Not applicableUs
ViagraTablet, orally disintegrating50 mgOralPfizer Limited1998-09-14Not applicableEu
ViagraTablet, film coated100 mg/1OralPd Rx Pharmaceuticals, Inc.1998-03-27Not applicableUs
ViagraTablet, film coated25 mg/1Oralbryant ranch prepack1998-03-27Not applicableUs
ViagraTablet, film coated50 mg/1OralPfizer Laboratories Div Pfizer Inc1998-03-27Not applicableUs
ViagraTablet, film coated25 mgOralPfizer Limited1998-09-14Not applicableEu
ViagraTablet, film coated50 mgOralPfizer Limited1998-09-14Not applicableEu
ViagraTablet, film coated50 mgOralPfizer Limited1998-09-14Not applicableEu
ViagraTablet, film coated100 mg/1Oralbryant ranch prepack1998-03-27Not applicableUs
ViagraTablet, film coated100 mg/1OralRebel Distributors Corp2010-02-11Not applicableUs
ViagraTablet, film coated50 mgOralPfizer Limited1998-09-14Not applicableEu
ViagraTablet, film coated25 mg/1OralPhysicians Total Care, Inc.1998-03-27Not applicableUs
ViagraTablet, film coated100 mg/1OralA S Medication Solutions1998-03-27Not applicableUs
ViagraTablet, film coated25 mgOralPfizer Limited1998-09-14Not applicableEu
ViagraTablet50 mgOralPfizer Canada Inc1999-03-09Not applicableCanada
ViagraTablet, film coated100 mg/1OralLake Erie Medical Surgical & Supply DBA Quality Care Products LLC2011-07-13Not applicableUs
ViagraTablet25 mgOralPfizer Canada Inc1999-03-09Not applicableCanada
ViagraTablet, film coated25 mgOralPfizer Limited1998-09-14Not applicableEu
ViagraTablet, orally disintegrating50 mgOralPfizer Limited1998-09-14Not applicableEu
ViagraTablet, film coated100 mg/1OralPfizer Laboratories Div Pfizer Inc1998-03-27Not applicableUs
ViagraTablet, film coated100 mgOralPfizer Limited1998-09-14Not applicableEu
ViagraTablet, film coated100 mgOralPfizer Limited1998-09-14Not applicableEu
ViagraTablet, film coated50 mg/1Oralbryant ranch prepack1998-03-27Not applicableUs
ViagraTablet, film coated25 mg/1OralPd Rx Pharmaceuticals, Inc.1998-03-27Not applicableUs
ViagraTablet, film coated50 mgOralPfizer Limited1998-09-14Not applicableEu
ViagraTablet, film coated25 mg/1OralCardinal Health1998-03-27Not applicableUs
ViagraTablet, film coated100 mg/1OralA S Medication Solutions1998-03-27Not applicableUs
ViagraTablet, film coated50 mgOralPfizer Limited1998-09-14Not applicableEu
ViagraTablet100 mgOralPfizer Canada Inc1999-03-09Not applicableCanada
ViagraTablet, film coated100 mg/1OralREMEDYREPACK INC.2013-05-22Not applicableUs
ViagraTablet, film coated50 mgOralPfizer Limited1998-09-14Not applicableEu
ViagraTablet, orally disintegrating50 mgOralPfizer Limited1998-09-14Not applicableEu
ViagraTablet, film coated50 mg/1OralU.S. Pharmaceuticals1998-03-27Not applicableUs
ViagraTablet, film coated100 mgOralPfizer Limited1998-09-14Not applicableEu
ViagraTablet, film coated50 mg/1OralAphena Pharma Solutions Tennessee, Llc1998-03-27Not applicableUs
ViagraTablet, film coated25 mg/1OralPfizer Laboratories Div Pfizer Inc1998-03-27Not applicableUs
ViagraTablet, film coated25 mgOralPfizer Limited1998-09-14Not applicableEu
ViagraTablet, film coated50 mgOralPfizer Limited1998-09-14Not applicableEu
ViagraTablet, film coated50 mg/1OralPd Rx Pharmaceuticals, Inc.1998-03-27Not applicableUs
ViagraTablet, film coated100 mgOralPfizer Limited1998-09-14Not applicableEu
ViagraTablet, film coated50 mg/1OralPhysicians Total Care, Inc.1998-03-27Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-sildenafilTablet25 mgOralApotex Inc2012-11-14Not applicableCanada
Apo-sildenafilTablet50 mgOralApotex Inc2012-11-14Not applicableCanada
Apo-sildenafilTablet100 mgOralApotex Inc2012-11-09Not applicableCanada
Apo-sildenafil RTablet20 mgOralApotex Inc2013-12-23Not applicableCanada
SildenafilTablet, film coated20 mg/1OralLake Erie Medical Dba Quality C2015-11-18Not applicableUs
SildenafilTablet, film coated20 mg/1OralNorthwind Pharmaceuticals, LLC2014-11-06Not applicableUs
SildenafilTablet20 mg/1OralAmerican Health Packaging2015-02-15Not applicableUs
SildenafilTablet, film coated20 mg/1OralTeva Pharmaceuticals USA Inc2013-05-31Not applicableUs
SildenafilTablet, film coated20 mg/1OralREMEDYREPACK INC.2015-12-10Not applicableUs
SildenafilTablet, film coated20 mg/1OralMacleods Pharmaceuticals Limited2014-01-03Not applicableUs
SildenafilTablet, film coated20 mg/1OralPd Rx Pharmaceuticals, Inc.2014-01-03Not applicableUs
SildenafilTablet20 mg/1OralBlue Point Laboratories2014-02-04Not applicableUs
SildenafilTablet, film coated20 mg/1OralPd Rx Pharmaceuticals, Inc.2013-05-31Not applicableUs
SildenafilTablet, film coated20 mg/1OralREMEDYREPACK INC.2013-09-192016-10-13Us
SildenafilInjection, solution10 mg/12.5mLIntravenousAuro Medics Pharma Llc2015-04-01Not applicableUs
SildenafilTablet, film coated20 mg/1OralActavis Pharma, Inc.2012-11-06Not applicableUs
SildenafilTablet20 mg/1Oralbryant ranch prepack2012-11-08Not applicableUs
SildenafilTablet, film coated20 mg/1OralAv Kare, Inc.2013-09-17Not applicableUs
SildenafilTablet, film coated20 mg/1OralPreferred Pharmaceuticals Inc.2016-08-25Not applicableUs
SildenafilTablet, film coated20 mg/1OralPreferred Pharmaceuticals Inc.2016-04-14Not applicableUs
SildenafilTablet, film coated20 mg/1OralDr. Reddy's Laboratories Limited2012-11-12Not applicableUs
SildenafilTablet, film coated20 mg/1OralDIRECT RX2015-01-01Not applicableUs
SildenafilTablet20 mg/1OralA S Medication Solutions2012-11-08Not applicableUs
SildenafilTablet, film coated20 mg/1OralNorthstar Rx LLC2013-02-262016-10-13Us
SildenafilTablet20 mg/1OralAmneal Pharmaceuticals of New York, LLC2012-11-08Not applicableUs
SildenafilTablet20 mg/1OralA S Medication Solutions2012-11-08Not applicableUs
SildenafilTablet20 mg/1OralAv Pak2015-05-29Not applicableUs
SildenafilTablet, film coated20 mg/1OralApotex Corp.2012-11-06Not applicableUs
SildenafilTablet, film coated20 mg/1OralCamber Pharmaceuticals, Inc.2014-11-26Not applicableUs
SildenafilTablet, film coated20 mg/1OralProficient Rx LP2014-11-26Not applicableUs
SildenafilTablet, film coated20 mg/1OralMylan Pharmaceuticals Inc.2012-11-09Not applicableUs
SildenafilTablet, film coated20 mg/1OralAurobindo Pharma Limited2015-11-18Not applicableUs
Sildenafil CitrateTablet20 mg/1OralTorrent Pharmaceuticals Limited2012-11-06Not applicableUs
Sildenafil CitrateTablet, film coated20 mg/1OralAmerican Health Packaging2012-12-142016-01-05Us
Sildenafil CitrateTablet, film coated20 mg/1OralVensun Pharmaceuticals, Inc.2016-08-01Not applicableUs
Sildenafil RatiopharmTablet, film coated25 mgOralRatiopharm Gmb H2009-12-23Not applicableEu
Sildenafil RatiopharmTablet, film coated50 mgOralRatiopharm Gmb H2009-12-23Not applicableEu
Sildenafil RatiopharmTablet, film coated50 mgOralRatiopharm Gmb H2009-12-23Not applicableEu
Sildenafil RatiopharmTablet, film coated25 mgOralRatiopharm Gmb H2009-12-23Not applicableEu
Sildenafil RatiopharmTablet, film coated100 mgOralRatiopharm Gmb H2009-12-23Not applicableEu
Sildenafil RatiopharmTablet, film coated50 mgOralRatiopharm Gmb H2009-12-23Not applicableEu
Sildenafil RatiopharmTablet, film coated50 mgOralRatiopharm Gmb H2009-12-23Not applicableEu
Sildenafil RatiopharmTablet, film coated25 mgOralRatiopharm Gmb H2009-12-23Not applicableEu
Sildenafil RatiopharmTablet, film coated100 mgOralRatiopharm Gmb H2009-12-23Not applicableEu
Sildenafil RatiopharmTablet, film coated100 mgOralRatiopharm Gmb H2009-12-23Not applicableEu
Sildenafil RatiopharmTablet, film coated100 mgOralRatiopharm Gmb H2009-12-23Not applicableEu
Sildenafil RatiopharmTablet, film coated50 mgOralRatiopharm Gmb H2009-12-23Not applicableEu
Sildenafil RatiopharmTablet, film coated25 mgOralRatiopharm Gmb H2009-12-23Not applicableEu
Sildenafil RatiopharmTablet, film coated100 mgOralRatiopharm Gmb H2009-12-23Not applicableEu
Sildenafil RatiopharmTablet, film coated25 mgOralRatiopharm Gmb H2009-12-23Not applicableEu
Sildenafil RatiopharmTablet, film coated100 mgOralRatiopharm Gmb H2009-12-23Not applicableEu
Sildenafil RatiopharmTablet, film coated100 mgOralRatiopharm Gmb H2009-12-23Not applicableEu
Sildenafil RatiopharmTablet, film coated50 mgOralRatiopharm Gmb H2009-12-23Not applicableEu
Sildenafil TevaTablet, film coated50 mgOralTeva B.V.  2009-11-30Not applicableEu
Sildenafil TevaTablet, film coated25 mgOralTeva B.V.  2009-11-30Not applicableEu
Sildenafil TevaTablet, film coated100 mgOralTeva B.V.  2009-11-30Not applicableEu
Sildenafil TevaTablet, film coated50 mgOralTeva B.V.  2009-11-30Not applicableEu
Sildenafil TevaTablet, film coated100 mgOralTeva B.V.  2009-11-30Not applicableEu
Sildenafil TevaTablet, film coated25 mgOralTeva B.V.  2009-11-30Not applicableEu
Sildenafil TevaTablet, film coated100 mgOralTeva B.V.  2009-11-30Not applicableEu
Sildenafil TevaTablet, film coated50 mgOralTeva B.V.  2009-11-30Not applicableEu
Sildenafil TevaTablet, film coated100 mgOralTeva B.V.  2009-11-30Not applicableEu
Sildenafil TevaTablet, film coated25 mgOralTeva B.V.  2009-11-30Not applicableEu
Sildenafil TevaTablet, film coated25 mgOralTeva B.V.  2009-11-30Not applicableEu
Sildenafil TevaTablet, film coated50 mgOralTeva B.V.  2009-11-30Not applicableEu
Sildenafil TevaTablet, film coated50 mgOralTeva B.V.  2009-11-30Not applicableEu
Sildenafil TevaTablet, film coated100 mgOralTeva B.V.  2009-11-30Not applicableEu
Sildenafil TevaTablet, film coated50 mgOralTeva B.V.  2009-11-30Not applicableEu
Sildenafil TevaTablet, film coated25 mgOralTeva B.V.  2009-11-30Not applicableEu
Sildenafil TevaTablet, film coated100 mgOralTeva B.V.  2009-11-30Not applicableEu
VizarsinTablet, orally disintegrating100 mgOralKrka, D.D., Novo Mesto2009-09-21Not applicableEu
VizarsinTablet, film coated50 mgOralKrka, D.D., Novo Mesto2009-09-21Not applicableEu
VizarsinTablet, orally disintegrating25 mgOralKrka, D.D., Novo Mesto2009-09-21Not applicableEu
VizarsinTablet, film coated25 mgOralKrka, D.D., Novo Mesto2009-09-21Not applicableEu
VizarsinTablet, film coated100 mgOralKrka, D.D., Novo Mesto2009-09-21Not applicableEu
VizarsinTablet, orally disintegrating100 mgOralKrka, D.D., Novo Mesto2009-09-21Not applicableEu
VizarsinTablet, film coated50 mgOralKrka, D.D., Novo Mesto2009-09-21Not applicableEu
VizarsinTablet, orally disintegrating50 mgOralKrka, D.D., Novo Mesto2009-09-21Not applicableEu
VizarsinTablet, orally disintegrating100 mgOralKrka, D.D., Novo Mesto2009-09-21Not applicableEu
VizarsinTablet, film coated100 mgOralKrka, D.D., Novo Mesto2009-09-21Not applicableEu
VizarsinTablet, orally disintegrating25 mgOralKrka, D.D., Novo Mesto2009-09-21Not applicableEu
VizarsinTablet, film coated25 mgOralKrka, D.D., Novo Mesto2009-09-21Not applicableEu
VizarsinTablet, orally disintegrating25 mgOralKrka, D.D., Novo Mesto2009-09-21Not applicableEu
VizarsinTablet, orally disintegrating50 mgOralKrka, D.D., Novo Mesto2009-09-21Not applicableEu
VizarsinTablet, film coated50 mgOralKrka, D.D., Novo Mesto2009-09-21Not applicableEu
VizarsinTablet, orally disintegrating50 mgOralKrka, D.D., Novo Mesto2009-09-21Not applicableEu
VizarsinTablet, orally disintegrating100 mgOralKrka, D.D., Novo Mesto2009-09-21Not applicableEu
VizarsinTablet, film coated100 mgOralKrka, D.D., Novo Mesto2009-09-21Not applicableEu
VizarsinTablet, orally disintegrating50 mgOralKrka, D.D., Novo Mesto2009-09-21Not applicableEu
VizarsinTablet, film coated25 mgOralKrka, D.D., Novo Mesto2009-09-21Not applicableEu
VizarsinTablet, orally disintegrating25 mgOralKrka, D.D., Novo Mesto2009-09-21Not applicableEu
VizarsinTablet, orally disintegrating100 mgOralKrka, D.D., Novo Mesto2009-09-21Not applicableEu
VizarsinTablet, orally disintegrating50 mgOralKrka, D.D., Novo Mesto2009-09-21Not applicableEu
VizarsinTablet, film coated50 mgOralKrka, D.D., Novo Mesto2009-09-21Not applicableEu
VizarsinTablet, film coated100 mgOralKrka, D.D., Novo Mesto2009-09-21Not applicableEu
VizarsinTablet, orally disintegrating100 mgOralKrka, D.D., Novo Mesto2009-09-21Not applicableEu
VizarsinTablet, film coated25 mgOralKrka, D.D., Novo Mesto2009-09-21Not applicableEu
VizarsinTablet, orally disintegrating50 mgOralKrka, D.D., Novo Mesto2009-09-21Not applicableEu
VizarsinTablet, orally disintegrating25 mgOralKrka, D.D., Novo Mesto2009-09-21Not applicableEu
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Sildenafil Citrate
171599-83-0
Thumb
  • InChI Key: DEIYFTQMQPDXOT-UHFFFAOYSA-N
  • Monoisotopic Mass: 666.231926778
  • Average Mass: 666.7
DBSALT000347
Categories
UNII3M7OB98Y7H
CAS number139755-83-2
WeightAverage: 474.576
Monoisotopic: 474.204924168
Chemical FormulaC22H30N6O4S
InChI KeyBNRNXUUZRGQAQC-UHFFFAOYSA-N
InChI
InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)
IUPAC Name
5-{2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-1-methyl-3-propyl-1H,4H,7H-pyrazolo[4,3-d]pyrimidin-7-one
SMILES
CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1
Pharmacology
IndicationFor the treatment of erectile dysfunction and to relieve symptoms of pulmonary arterial hypertension (PAH).
Structured Indications
PharmacodynamicsErections are controlled by the parasympathetic nervous system. Upon sexual stimulation, a decrease in vascular resistance is mediated by acetylcholine and nitric oxide resulting in vasodilation. The hemodynamic mechanism of an erection is comprised of five stages. During the latent stage, arterial and carvernous smooth muscle relaxation occurs. Vasodilation results in high levels of blood flow causing the penis to grow to its full size. This stage is called tumescence. During the full-erection stage, blood flow fills penis sinusoids and outflow is restricted. This is followed by the rigid-erection phase during which the cavernous muscles contract causing the penis to become rigid. Little blood flow occurs during this stage. During the final stage, detumescence, the cavernous muscles relax and blood flows out of the penis. Erectile dysfunction may occur when there is insufficient blood supply to the penis or when the penis is unable to prevent outflow of blood from the penis. Sildenafil is a specific inhibitor of PDE5, an enzyme responsible for the breakdown of cGMP to 5’-GMP. Increased levels of cGMP stimulate vasodilation and facilitate the generation and maintenance of erections. These vasodilatory effects also help decrease symptoms of PAH. Sildenfail also exhibits some activity against PDE6 (10 times less potentcy compared to PDE5), a PDE isoform found predmoninantly in the retina. This activity is responsible for the blue tinged vision experienced by users of sildenafil.
Mechanism of actionSildenafil inhibits the cGMP-specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum located around the penis. Penile erection during sexual stimulation is caused by increased penile blood flow resulting from the relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. The inhibition of phosphodiesterase type 5 (PDE5) by sildenafil enhances erectile function by increasing the amount of cGMP.
TargetKindPharmacological actionActionsOrganismUniProt ID
cGMP-specific 3',5'-cyclic phosphodiesteraseProteinyes
inhibitor
HumanO76074 details
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammaProteinno
inhibitor
HumanP18545 details
Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammaProteinno
inhibitor
HumanQ13956 details
Related Articles
Absorption>90% absorbed with ~40% reaching systemic circulation unchanged following first-pass metabolism
Volume of distribution
  • 105 L
Protein binding96%
Metabolism

Sildenafil appears to be completely metabolized in the liver to 16 metabolites. Its metabolism is mediated mainly by cytochrome P450 microsomal isozymes 3A4 (major route) and 2C9 (minor route). The major circulating metabolite, N-demethylated metabolite, has PDE selectivity similar to the parent drug and ~50% of its in vitro potency. The N-demethylated metabolite is further metabolized to an N-dealkylated N,N-de-ethylated metabolite. Sildenafil also undergoes N-dealkylation followed by N-demethylation of the piperazine ring.

SubstrateEnzymesProduct
Sildenafil
N-Desmethyl sildenafil (UK-103,320)Details
Route of eliminationSildenafil is cleared predominantly by the CYP3A (major route) and cytochrome P450 2C9 (CYP2C9, minor route) hepatic microsomal isoenzymes. After either oral or intravenous administration, sildenafil is excreted as metabolites predominantly in the feces (approximately 80% of the administered oral dose) and to a lesser extent in the urine (approximately 13% of the administered oral dose).
Half life4 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Angiotensin-converting enzyme
Gene symbol: ACE
UniProt: P12821
rs1799752 Not AvailableAlu insertionsBetter response to drug treatment12837457
Angiotensin-converting enzyme
Gene symbol: ACE
UniProt: P12821
rs4340 Not AvailableAlu insertionsBetter response to drug treatment12837457
Angiotensin-converting enzyme
Gene symbol: ACE
UniProt: P12821
rs13447447 Not AvailableAlu insertionsBetter response to drug treatment12837457
Angiotensin-converting enzyme
Gene symbol: ACE
UniProt: P12821
rs4646994 Not AvailableAlu insertionsBetter response to drug treatment12837457
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3
Gene symbol: GNB3
UniProt: P16520
rs5443 Not AvailableT AlleleBetter response to drug treatment12576843
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3
Gene symbol: GNB3
UniProt: P16520
rs5443 Not AvailableTT alleleBetter response to drug treatment. More patients experience a 'postive erectile response'12576843
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Sildenafil can be increased when it is combined with 1,10-Phenanthroline.Experimental
3,4-DichloroisocoumarinThe serum concentration of Sildenafil can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Sildenafil can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.Experimental
AbirateroneThe serum concentration of Sildenafil can be increased when it is combined with Abiraterone.Approved
AcebutololSildenafil may increase the antihypertensive activities of Acebutolol.Approved
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Sildenafil.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Sildenafil.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Sildenafil.Approved
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Sildenafil.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Sildenafil.Approved
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Sildenafil.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Sildenafil.Approved
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Sildenafil.Approved, Illicit
AlfuzosinSildenafil may increase the hypotensive activities of Alfuzosin.Approved, Investigational
AliskirenSildenafil may increase the antihypertensive activities of Aliskiren.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Sildenafil.Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Sildenafil.Approved, Investigational
AlogliptinThe serum concentration of Sildenafil can be increased when it is combined with Alogliptin.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Sildenafil.Approved, Withdrawn
Alpha-1-proteinase inhibitorThe serum concentration of Sildenafil can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Sildenafil.Approved, Illicit, Investigational
AlprenololSildenafil may increase the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe risk or severity of adverse effects can be increased when Sildenafil is combined with Alprostadil.Approved, Investigational
AmbrisentanSildenafil may increase the antihypertensive activities of Ambrisentan.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Sildenafil.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Sildenafil.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Sildenafil.Approved
AmiodaroneThe serum concentration of Sildenafil can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Sildenafil.Approved
AmlodipineSildenafil may increase the antihypertensive activities of Amlodipine.Approved
AmprenavirThe serum concentration of Sildenafil can be increased when it is combined with Amprenavir.Approved
Amyl NitriteSildenafil may increase the vasodilatory activities of Amyl Nitrite.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Sildenafil.Approved
Antithrombin III humanThe serum concentration of Sildenafil can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Sildenafil can be increased when it is combined with Apixaban.Approved
ApremilastThe metabolism of Apremilast can be decreased when combined with Sildenafil.Approved, Investigational
AprepitantThe serum concentration of Sildenafil can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Sildenafil can be increased when it is combined with Aprotinin.Approved, Withdrawn
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Sildenafil.Experimental
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Sildenafil.Approved, Investigational
ArgatrobanThe serum concentration of Sildenafil can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Sildenafil.Approved, Investigational
ArmodafinilThe metabolism of Sildenafil can be decreased when combined with Armodafinil.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Sildenafil.Approved
AsenapineThe metabolism of Asenapine can be decreased when combined with Sildenafil.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Sildenafil.Approved, Withdrawn
AsunaprevirThe serum concentration of Sildenafil can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe serum concentration of Sildenafil can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololSildenafil may increase the antihypertensive activities of Atenolol.Approved
AtomoxetineThe metabolism of Sildenafil can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Sildenafil.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Sildenafil.Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Sildenafil.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Sildenafil.Approved
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Sildenafil.Approved
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Sildenafil.Investigational
BatimastatThe serum concentration of Sildenafil can be increased when it is combined with Batimastat.Experimental
BedaquilineThe metabolism of Bedaquiline can be decreased when combined with Sildenafil.Approved
BenazeprilThe serum concentration of Sildenafil can be increased when it is combined with Benazepril.Approved, Investigational
BendroflumethiazideSildenafil may increase the antihypertensive activities of Bendroflumethiazide.Approved
BenzamidineThe serum concentration of Sildenafil can be increased when it is combined with Benzamidine.Experimental
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Sildenafil.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Sildenafil.Approved
BepridilSildenafil may increase the antihypertensive activities of Bepridil.Approved, Withdrawn
BetaxololSildenafil may increase the antihypertensive activities of Betaxolol.Approved
BethanidineSildenafil may increase the antihypertensive activities of Bethanidine.Approved
BexaroteneThe serum concentration of Sildenafil can be decreased when it is combined with Bexarotene.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Sildenafil.Approved
Bi201335The serum concentration of Sildenafil can be increased when it is combined with Bi201335.Investigational
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Sildenafil.Approved
BimatoprostSildenafil may increase the antihypertensive activities of Bimatoprost.Approved, Investigational
BisoprololSildenafil may increase the antihypertensive activities of Bisoprolol.Approved
BivalirudinThe serum concentration of Sildenafil can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Sildenafil can be increased when it is combined with Boceprevir.Approved
BortezomibThe metabolism of Sildenafil can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Sildenafil.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Sildenafil.Approved
Brentuximab vedotinThe metabolism of Brentuximab vedotin can be decreased when combined with Sildenafil.Approved
BretyliumSildenafil may increase the antihypertensive activities of Bretylium.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Sildenafil.Approved
BrimonidineSildenafil may increase the antihypertensive activities of Brimonidine.Approved
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Sildenafil.Approved
BromazepamThe metabolism of Bromazepam can be decreased when combined with Sildenafil.Approved, Illicit
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Sildenafil.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Sildenafil.Approved
BucindololSildenafil may increase the hypotensive activities of Bucindolol.Investigational
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Sildenafil.Approved
BudesonideThe metabolism of Budesonide can be decreased when combined with Sildenafil.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Sildenafil.Approved, Investigational
BupranololSildenafil may increase the antihypertensive activities of Bupranolol.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Sildenafil.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Sildenafil can be decreased when combined with Bupropion.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Sildenafil.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Sildenafil.Approved, Investigational
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Sildenafil.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Sildenafil.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Sildenafil.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Sildenafil.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Sildenafil.Approved, Nutraceutical
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Sildenafil.Approved
CandesartanSildenafil may increase the antihypertensive activities of Candesartan.Approved
CandoxatrilThe serum concentration of Sildenafil can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Sildenafil can be increased when it is combined with Candoxatrilat.Experimental
CapecitabineThe metabolism of Sildenafil can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe serum concentration of Sildenafil can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Sildenafil can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Sildenafil.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Sildenafil.Approved
CarteololSildenafil may increase the antihypertensive activities of Carteolol.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Sildenafil.Approved, Investigational
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Sildenafil.Approved, Investigational
CeliprololSildenafil may increase the antihypertensive activities of Celiprolol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Sildenafil.Approved, Vet Approved
CeritinibThe serum concentration of Sildenafil can be increased when it is combined with Ceritinib.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Sildenafil.Withdrawn
CevimelineThe metabolism of Cevimeline can be decreased when combined with Sildenafil.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Sildenafil.Approved
ChloramphenicolThe metabolism of Sildenafil can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Sildenafil.Approved, Illicit
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Sildenafil.Approved, Vet Approved
ChlorothiazideSildenafil may increase the antihypertensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Sildenafil.Approved
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Sildenafil.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Sildenafil.Approved
ChlorthalidoneSildenafil may increase the antihypertensive activities of Chlorthalidone.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Sildenafil.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Sildenafil.Approved, Nutraceutical
ChymostatinThe serum concentration of Sildenafil can be increased when it is combined with Chymostatin.Experimental
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Sildenafil.Approved, Investigational
CilastatinThe serum concentration of Sildenafil can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Sildenafil can be increased when it is combined with Cilazapril.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Sildenafil.Approved
CimetidineThe metabolism of Sildenafil can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Sildenafil can be decreased when combined with Cinacalcet.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Sildenafil.Approved
CisaprideThe metabolism of Cisapride can be decreased when combined with Sildenafil.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Citalopram can be decreased when combined with Sildenafil.Approved
ClarithromycinThe serum concentration of Sildenafil can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Sildenafil can be decreased when combined with Clemastine.Approved
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Sildenafil.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Sildenafil.Approved, Illicit
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Sildenafil.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Sildenafil.Approved
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Sildenafil.Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Sildenafil.Approved, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Sildenafil.Approved, Illicit
ClonidineSildenafil may increase the antihypertensive activities of Clonidine.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Sildenafil.Approved, Nutraceutical
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Sildenafil.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Sildenafil.Approved, Illicit
ClotrimazoleThe metabolism of Sildenafil can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Sildenafil.Approved
CobicistatThe serum concentration of Sildenafil can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Sildenafil.Approved
CocaineThe metabolism of Sildenafil can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe metabolism of Codeine can be decreased when combined with Sildenafil.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Sildenafil.Approved
ConivaptanThe serum concentration of Sildenafil can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Sildenafil.Approved
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Sildenafil.Approved
CrizotinibThe metabolism of Crizotinib can be decreased when combined with Sildenafil.Approved
CryptenamineSildenafil may increase the antihypertensive activities of Cryptenamine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Sildenafil.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Sildenafil.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Sildenafil.Approved, Investigational, Vet Approved
CyclothiazideSildenafil may increase the antihypertensive activities of Cyclothiazide.Approved
Cyproterone acetateThe serum concentration of Sildenafil can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CytarabineThe metabolism of Cytarabine can be decreased when combined with Sildenafil.Approved, Investigational
Dabigatran etexilateThe serum concentration of Sildenafil can be increased when it is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Sildenafil can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Sildenafil.Approved
DantroleneThe metabolism of Dantrolene can be decreased when combined with Sildenafil.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Sildenafil.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Sildenafil.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Sildenafil.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Sildenafil.Approved, Investigational
DarunavirThe serum concentration of Sildenafil can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Sildenafil.Approved
DasatinibThe serum concentration of Sildenafil can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Sildenafil.Approved
DebrisoquinSildenafil may increase the antihypertensive activities of Debrisoquin.Approved
DeferasiroxThe serum concentration of Sildenafil can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Sildenafil can be decreased when combined with Delavirdine.Approved
DeserpidineSildenafil may increase the antihypertensive activities of Deserpidine.Approved
DesipramineThe metabolism of Sildenafil can be decreased when combined with Desipramine.Approved
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Sildenafil.Approved
DexamethasoneThe serum concentration of Sildenafil can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sildenafil.Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Sildenafil.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Sildenafil.Approved, Illicit, Withdrawn
DiazepamThe metabolism of Diazepam can be decreased when combined with Sildenafil.Approved, Illicit, Vet Approved
DiazoxideSildenafil may increase the antihypertensive activities of Diazoxide.Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Sildenafil.Approved, Vet Approved
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Sildenafil.Approved
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Sildenafil.Approved
DigoxinThe metabolism of Digoxin can be decreased when combined with Sildenafil.Approved
DihydralazineSildenafil may increase the antihypertensive activities of Dihydralazine.Investigational
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Sildenafil.Approved, Illicit
DihydroergotamineThe metabolism of Sildenafil can be decreased when combined with Dihydroergotamine.Approved
DiltiazemSildenafil may increase the antihypertensive activities of Diltiazem.Approved
DiphenhydramineThe metabolism of Sildenafil can be decreased when combined with Diphenhydramine.Approved
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Sildenafil.Approved
DisulfiramThe metabolism of Sildenafil can be decreased when combined with Disulfiram.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Sildenafil.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Sildenafil.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Sildenafil.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Sildenafil.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Sildenafil.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Sildenafil.Approved
DorzolamideSildenafil may increase the antihypertensive activities of Dorzolamide.Approved
DoxazosinSildenafil may increase the hypotensive activities of Doxazosin.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Sildenafil.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Sildenafil.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Sildenafil.Approved, Investigational
DoxycyclineThe metabolism of Sildenafil can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Sildenafil.Approved, Illicit
DronedaroneThe metabolism of Dronedarone can be decreased when combined with Sildenafil.Approved
DuloxetineThe metabolism of Sildenafil can be decreased when combined with Duloxetine.Approved
DutasterideThe metabolism of Dutasteride can be decreased when combined with Sildenafil.Approved, Investigational
EcabetThe serum concentration of Sildenafil can be increased when it is combined with Ecabet.Approved, Investigational
EdoxabanThe serum concentration of Sildenafil can be increased when it is combined with Edoxaban.Approved
EfavirenzThe serum concentration of Sildenafil can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineSildenafil may increase the antihypertensive activities of Efonidipine.Approved
ElafinThe serum concentration of Sildenafil can be increased when it is combined with Elafin.Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Sildenafil.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Sildenafil.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Sildenafil.Approved
EnalaprilThe serum concentration of Sildenafil can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Sildenafil can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Sildenafil can be increased when it is combined with Enalkiren.Experimental
EnzalutamideThe serum concentration of Sildenafil can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Sildenafil.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Sildenafil.Approved
EpoprostenolSildenafil may increase the antihypertensive activities of Epoprostenol.Approved
EprosartanSildenafil may increase the antihypertensive activities of Eprosartan.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Sildenafil.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Sildenafil.Approved
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Sildenafil.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Sildenafil.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Sildenafil.Approved, Investigational
Erythrityl TetranitrateSildenafil may increase the vasodilatory activities of Erythrityl Tetranitrate.Approved
ErythromycinThe serum concentration of Sildenafil can be increased when it is combined with Erythromycin.Approved, Vet Approved
ErythromycinThe metabolism of Sildenafil can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Sildenafil.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Sildenafil can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Sildenafil.Approved, Investigational
EstazolamThe metabolism of Estazolam can be decreased when combined with Sildenafil.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Sildenafil.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Sildenafil.Approved
EstramustineThe metabolism of Estramustine can be decreased when combined with Sildenafil.Approved
EstroneThe metabolism of Estrone can be decreased when combined with Sildenafil.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Sildenafil.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Sildenafil.Approved
EthanolEthanol may increase the hypotensive activities of Sildenafil.Approved
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Sildenafil.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Sildenafil.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Sildenafil.Approved, Illicit
EtodolacThe metabolism of Etodolac can be decreased when combined with Sildenafil.Approved, Investigational, Vet Approved
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Sildenafil.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Sildenafil.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Sildenafil.Approved, Investigational
EtravirineThe serum concentration of Sildenafil can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Sildenafil.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Sildenafil.Approved, Investigational
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Sildenafil.Approved
FelbamateThe metabolism of Felbamate can be decreased when combined with Sildenafil.Approved
FelodipineSildenafil may increase the antihypertensive activities of Felodipine.Approved, Investigational
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Sildenafil.Approved
FenoldopamSildenafil may increase the antihypertensive activities of Fenoldopam.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Sildenafil.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sildenafil.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Sildenafil.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Sildenafil.Approved, Investigational
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Sildenafil.Approved
FloxuridineThe metabolism of Sildenafil can be decreased when combined with Floxuridine.Approved
FluconazoleThe serum concentration of Sildenafil can be increased when it is combined with Fluconazole.Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Sildenafil.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Sildenafil.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Sildenafil.Approved, Illicit
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Sildenafil.Approved
FluorouracilThe metabolism of Sildenafil can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Sildenafil can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Sildenafil.Approved, Illicit
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Sildenafil.Approved, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Sildenafil.Approved
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Sildenafil.Approved
Fluticasone PropionateThe metabolism of Fluticasone Propionate can be decreased when combined with Sildenafil.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Sildenafil.Approved
FluvoxamineThe metabolism of Sildenafil can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Sildenafil.Approved, Investigational
FosamprenavirThe serum concentration of Sildenafil can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Sildenafil can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Sildenafil can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Sildenafil can be increased when combined with Fosphenytoin.Approved
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Sildenafil.Approved, Investigational
Fusidic AcidThe serum concentration of Sildenafil can be increased when it is combined with Fusidic Acid.Approved
GabexateThe serum concentration of Sildenafil can be increased when it is combined with Gabexate.Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Sildenafil.Approved
GavestinelThe metabolism of Gavestinel can be decreased when combined with Sildenafil.Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Sildenafil.Approved, Investigational
GeldanamycinThe serum concentration of Sildenafil can be increased when it is combined with Geldanamycin.Experimental
GemfibrozilThe metabolism of Sildenafil can be decreased when combined with Gemfibrozil.Approved
GliclazideThe metabolism of Gliclazide can be decreased when combined with Sildenafil.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Sildenafil.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Sildenafil.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Sildenafil.Approved
GM6001The serum concentration of Sildenafil can be increased when it is combined with GM6001.Experimental
GranisetronThe metabolism of Granisetron can be decreased when combined with Sildenafil.Approved, Investigational
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Sildenafil.Withdrawn
GuanabenzSildenafil may increase the antihypertensive activities of Guanabenz.Approved
GuanadrelSildenafil may increase the antihypertensive activities of Guanadrel.Approved
GuanethidineSildenafil may increase the antihypertensive activities of Guanethidine.Approved
GuanfacineSildenafil may increase the antihypertensive activities of Guanfacine.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Sildenafil.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Sildenafil.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Sildenafil.Approved, Vet Approved
HexamethoniumSildenafil may increase the antihypertensive activities of Hexamethonium.Experimental
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Sildenafil.Approved
HirulogThe serum concentration of Sildenafil can be increased when it is combined with Hirulog.Experimental
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Sildenafil.Approved
HydralazineSildenafil may increase the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideSildenafil may increase the antihypertensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Sildenafil.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Sildenafil.Approved, Vet Approved
HydroflumethiazideSildenafil may increase the antihypertensive activities of Hydroflumethiazide.Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Sildenafil.Approved, Illicit
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Sildenafil.Approved
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Sildenafil.Approved
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Sildenafil.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Sildenafil.Approved
IdelalisibThe serum concentration of Sildenafil can be increased when it is combined with Idelalisib.Approved
idraparinuxThe serum concentration of Sildenafil can be increased when it is combined with idraparinux.Investigational
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Sildenafil resulting in a loss in efficacy.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Sildenafil.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Sildenafil.Approved
ImidaprilThe serum concentration of Sildenafil can be increased when it is combined with Imidapril.Investigational
ImipramineThe metabolism of Imipramine can be decreased when combined with Sildenafil.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Sildenafil.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Sildenafil.Approved
IndapamideSildenafil may increase the antihypertensive activities of Indapamide.Approved
IndenololSildenafil may increase the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Sildenafil can be increased when it is combined with Indinavir.Approved
indisulamThe metabolism of indisulam can be decreased when combined with Sildenafil.Investigational
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Sildenafil.Approved, Investigational
IndoraminSildenafil may increase the hypotensive activities of Indoramin.Withdrawn
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Sildenafil.Approved
IrbesartanSildenafil may increase the antihypertensive activities of Irbesartan.Approved, Investigational
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Sildenafil.Approved, Investigational
IsavuconazoniumThe metabolism of Isavuconazonium can be decreased when combined with Sildenafil.Approved, Investigational
IsoflurophateThe serum concentration of Sildenafil can be increased when it is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe metabolism of Sildenafil can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateSildenafil may increase the vasodilatory activities of Isosorbide Dinitrate.Approved
Isosorbide MononitrateSildenafil may increase the vasodilatory activities of Isosorbide Mononitrate.Approved
IsradipineSildenafil may increase the antihypertensive activities of Isradipine.Approved
ItraconazoleThe serum concentration of Sildenafil can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Sildenafil.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Sildenafil.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Sildenafil.Approved, Vet Approved
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Sildenafil.Approved, Investigational
IxazomibThe serum concentration of Sildenafil can be increased when it is combined with Ixazomib.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Sildenafil.Approved, Vet Approved
KetanserinSildenafil may increase the antihypertensive activities of Ketanserin.Investigational
KetazolamThe metabolism of Ketazolam can be decreased when combined with Sildenafil.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Sildenafil.Approved
KetoconazoleThe serum concentration of Sildenafil can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Sildenafil.Approved, Vet Approved
LabetalolSildenafil may increase the hypotensive activities of Labetalol.Approved
LacidipineSildenafil may increase the antihypertensive activities of Lacidipine.Approved
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Sildenafil.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Sildenafil.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Sildenafil.Investigational
LatanoprostSildenafil may increase the antihypertensive activities of Latanoprost.Approved, Investigational
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Sildenafil.Approved, Investigational
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Sildenafil.Approved
LepirudinThe serum concentration of Sildenafil can be increased when it is combined with Lepirudin.Approved
LercanidipineSildenafil may increase the antihypertensive activities of Lercanidipine.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be decreased when combined with Sildenafil.Approved
LetrozoleThe metabolism of Letrozole can be decreased when combined with Sildenafil.Approved, Investigational
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Sildenafil.Approved
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Sildenafil.Approved
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Sildenafil.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Sildenafil.Approved
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Sildenafil.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Sildenafil.Approved
LicofeloneThe metabolism of Licofelone can be decreased when combined with Sildenafil.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Sildenafil.Approved, Vet Approved
LinagliptinThe serum concentration of Sildenafil can be increased when it is combined with Linagliptin.Approved
LisinoprilThe serum concentration of Sildenafil can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Sildenafil.Approved
LofexidineSildenafil may increase the antihypertensive activities of Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Sildenafil.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Sildenafil.Approved
LopinavirThe serum concentration of Sildenafil can be increased when it is combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Sildenafil.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Sildenafil.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Sildenafil.Approved
LosartanSildenafil may increase the antihypertensive activities of Losartan.Approved
LovastatinThe metabolism of Sildenafil can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Sildenafil can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Sildenafil can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Lumefantrine can be decreased when combined with Sildenafil.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Sildenafil.Approved, Investigational
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Sildenafil.Approved
MacitentanSildenafil may increase the antihypertensive activities of Macitentan.Approved
ManidipineSildenafil may increase the antihypertensive activities of Manidipine.Approved
MaravirocThe metabolism of Maraviroc can be decreased when combined with Sildenafil.Approved, Investigational
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Sildenafil.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Sildenafil is combined with Mecamylamine.Approved
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Sildenafil.Approved, Investigational
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Sildenafil.Approved
MefloquineThe metabolism of Mefloquine can be decreased when combined with Sildenafil.Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Sildenafil.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Sildenafil.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Sildenafil.Investigational, Withdrawn
MestranolThe metabolism of Mestranol can be decreased when combined with Sildenafil.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Sildenafil.Approved
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Sildenafil.Illicit, Withdrawn
MethotrimeprazineThe metabolism of Sildenafil can be decreased when combined with Methotrimeprazine.Approved
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Sildenafil.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Sildenafil.Approved, Vet Approved
MethyldopaSildenafil may increase the antihypertensive activities of Methyldopa.Approved
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Sildenafil.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Sildenafil.Approved
MetipranololSildenafil may increase the antihypertensive activities of Metipranolol.Approved
MetolazoneSildenafil may increase the antihypertensive activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Sildenafil.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Sildenafil.Approved
MetyrosineSildenafil may increase the antihypertensive activities of Metyrosine.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Sildenafil.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Sildenafil.Approved
MibefradilSildenafil may increase the antihypertensive activities of Mibefradil.Withdrawn
MiconazoleThe metabolism of Miconazole can be decreased when combined with Sildenafil.Approved, Investigational, Vet Approved
MidazolamThe metabolism of Midazolam can be decreased when combined with Sildenafil.Approved, Illicit
MifepristoneThe serum concentration of Sildenafil can be increased when it is combined with Mifepristone.Approved, Investigational
MinoxidilSildenafil may increase the antihypertensive activities of Minoxidil.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Sildenafil.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Sildenafil.Approved
MitotaneThe serum concentration of Sildenafil can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Sildenafil can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Sildenafil can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Sildenafil can be increased when it is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Sildenafil.Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Sildenafil.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Sildenafil.Approved, Investigational
MoxonidineSildenafil may increase the antihypertensive activities of Moxonidine.Approved
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Sildenafil.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Sildenafil can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NadololSildenafil may increase the antihypertensive activities of Nadolol.Approved
NafamostatThe serum concentration of Sildenafil can be increased when it is combined with Nafamostat.Investigational
NafcillinThe serum concentration of Sildenafil can be decreased when it is combined with Nafcillin.Approved
NaftopidilSildenafil may increase the antihypertensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Sildenafil.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Sildenafil.Approved, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Sildenafil.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Sildenafil.Approved, Investigational
NCX 4016The serum concentration of Sildenafil can be increased when it is combined with NCX 4016.Investigational
NebivololSildenafil may increase the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Sildenafil can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Sildenafil can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Sildenafil can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Sildenafil can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Sildenafil can be decreased when combined with Nicardipine.Approved
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Sildenafil.Approved, Vet Approved
NicorandilSildenafil may increase the antihypertensive activities of Nicorandil.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Sildenafil.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Sildenafil.Approved
NiguldipineSildenafil may increase the antihypertensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Nilotinib can be decreased when combined with Sildenafil.Approved, Investigational
NilvadipineSildenafil may increase the antihypertensive activities of Nilvadipine.Approved
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Sildenafil.Approved
NisoldipineSildenafil may increase the antihypertensive activities of Nisoldipine.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Sildenafil.Approved
NitrendipineSildenafil may increase the antihypertensive activities of Nitrendipine.Approved
NitroaspirinThe serum concentration of Sildenafil can be increased when it is combined with Nitroaspirin.Investigational
NitroglycerinSildenafil may increase the vasodilatory activities of Nitroglycerin.Approved, Investigational
NitroprussideSildenafil may increase the antihypertensive activities of Nitroprusside.Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Sildenafil.Approved
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Sildenafil.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Sildenafil.Approved
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Sildenafil.Approved
OlmesartanSildenafil may increase the antihypertensive activities of Olmesartan.Approved, Investigational
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Sildenafil.Approved
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Sildenafil.Approved
OmapatrilatThe serum concentration of Sildenafil can be increased when it is combined with Omapatrilat.Investigational
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Sildenafil.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Sildenafil.Approved
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Sildenafil.Approved
OsimertinibThe serum concentration of Sildenafil can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Sildenafil.Approved
OtamixabanThe serum concentration of Sildenafil can be increased when it is combined with Otamixaban.Investigational
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Sildenafil.Approved
OxazepamThe metabolism of Oxazepam can be decreased when combined with Sildenafil.Approved
OxprenololSildenafil may increase the antihypertensive activities of Oxprenolol.Approved
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Sildenafil.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Sildenafil is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Sildenafil.Approved, Investigational, Vet Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Sildenafil.Approved, Vet Approved
PalbociclibThe serum concentration of Sildenafil can be increased when it is combined with Palbociclib.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Sildenafil.Approved, Investigational
PanobinostatThe serum concentration of Sildenafil can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Sildenafil.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Sildenafil.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Sildenafil.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Sildenafil.Approved
PargylineSildenafil may increase the antihypertensive activities of Pargyline.Approved
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Sildenafil.Approved, Investigational
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Sildenafil.Approved
ParoxetineThe metabolism of Sildenafil can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe metabolism of Pazopanib can be decreased when combined with Sildenafil.Approved
Peginterferon alfa-2bThe serum concentration of Sildenafil can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololSildenafil may increase the antihypertensive activities of Penbutolol.Approved, Investigational
PentamidineThe metabolism of Pentamidine can be decreased when combined with Sildenafil.Approved
PentobarbitalThe metabolism of Sildenafil can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumSildenafil may increase the antihypertensive activities of Pentolinium.Approved
PerampanelThe metabolism of Perampanel can be decreased when combined with Sildenafil.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Sildenafil.Approved, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Sildenafil.Approved
PerindoprilThe serum concentration of Sildenafil can be increased when it is combined with Perindopril.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Sildenafil.Approved, Investigational
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Sildenafil.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Sildenafil.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Sildenafil.Withdrawn
PhenobarbitalThe metabolism of Sildenafil can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineSildenafil may increase the antihypertensive activities of Phenoxybenzamine.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Sildenafil.Approved
PhentolamineSildenafil may increase the antihypertensive activities of Phentolamine.Approved
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Sildenafil.Approved, Vet Approved
PhenytoinThe metabolism of Sildenafil can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Sildenafil can be increased when it is combined with Phosphoramidon.Experimental
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Sildenafil.Approved
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Sildenafil.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Sildenafil.Approved
PinacidilSildenafil may increase the antihypertensive activities of Pinacidil.Withdrawn
PindololSildenafil may increase the antihypertensive activities of Pindolol.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Sildenafil.Approved, Investigational
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Sildenafil.Approved
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Sildenafil.Approved, Investigational
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Sildenafil.Approved
PodofiloxThe metabolism of Podofilox can be decreased when combined with Sildenafil.Approved
PolythiazideSildenafil may increase the antihypertensive activities of Polythiazide.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Sildenafil.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Sildenafil.Approved
PosaconazoleThe serum concentration of Sildenafil can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrasteroneThe metabolism of Prasterone can be decreased when combined with Sildenafil.Approved, Nutraceutical
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Sildenafil.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Sildenafil.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Sildenafil.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Sildenafil.Approved, Vet Approved
PrazosinSildenafil may increase the hypotensive activities of Prazosin.Approved
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Sildenafil.Approved, Vet Approved
PrednisoneThe metabolism of Prednisone can be decreased when combined with Sildenafil.Approved, Vet Approved
PrimaquineThe metabolism of Primaquine can be decreased when combined with Sildenafil.Approved
PrimidoneThe metabolism of Sildenafil can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Sildenafil can be increased when it is combined with Prinomastat.Investigational
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Sildenafil.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Sildenafil.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Sildenafil.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Sildenafil.Approved, Vet Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Sildenafil.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Sildenafil.Approved, Investigational, Vet Approved
PropranololSildenafil may increase the antihypertensive activities of Propranolol.Approved, Investigational
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Sildenafil.Approved
PyrimethamineThe metabolism of Sildenafil can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Sildenafil.Approved, Illicit
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Sildenafil.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Sildenafil.Approved
QuinaprilThe serum concentration of Sildenafil can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineThe metabolism of Sildenafil can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Sildenafil.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Sildenafil.Approved, Investigational
RacecadotrilThe serum concentration of Sildenafil can be increased when it is combined with Racecadotril.Investigational
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Sildenafil.Approved, Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Sildenafil.Approved, Investigational
RamiprilThe serum concentration of Sildenafil can be increased when it is combined with Ramipril.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Sildenafil.Approved, Investigational
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Sildenafil.Approved, Investigational
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Sildenafil.Approved
RemikirenThe serum concentration of Sildenafil can be increased when it is combined with Remikiren.Approved
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Sildenafil.Approved, Investigational
RescinnamineSildenafil may increase the antihypertensive activities of Rescinnamine.Approved
ReserpineSildenafil may increase the antihypertensive activities of Reserpine.Approved
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Sildenafil.Approved
RifabutinThe metabolism of Sildenafil can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Sildenafil can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Sildenafil can be increased when combined with Rifapentine.Approved
RilmenidineSildenafil may increase the antihypertensive activities of Rilmenidine.Investigational
RilpivirineThe metabolism of Rilpivirine can be decreased when combined with Sildenafil.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Sildenafil.Approved, Investigational
RiociguatSildenafil may increase the hypotensive activities of Riociguat.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Sildenafil.Approved, Investigational
RitonavirThe serum concentration of Sildenafil can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Sildenafil can be increased when it is combined with Rivaroxaban.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Sildenafil.Investigational, Withdrawn
RolapitantThe metabolism of Rolapitant can be decreased when combined with Sildenafil.Approved
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Sildenafil.Approved, Investigational
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Sildenafil.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Sildenafil.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Sildenafil.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Sildenafil.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Sildenafil.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Sildenafil.Approved, Withdrawn
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Sildenafil.Approved
Salicylic acidThe metabolism of Salicylic acid can be decreased when combined with Sildenafil.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Sildenafil.Approved
SaprisartanSildenafil may increase the antihypertensive activities of Saprisartan.Experimental
SapropterinSapropterin may increase the hypotensive activities of Sildenafil.Approved, Investigational
SaquinavirThe serum concentration of Sildenafil can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Sildenafil can be increased when it is combined with Saxagliptin.Approved
SecobarbitalThe metabolism of Sildenafil can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Sildenafil.Approved, Investigational, Vet Approved
SelexipagSildenafil may increase the antihypertensive activities of Selexipag.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Sildenafil.Approved, Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Sildenafil.Approved, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Sildenafil.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Sildenafil.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Sildenafil.Approved, Illicit, Investigational, Withdrawn
SilodosinSildenafil may increase the hypotensive activities of Silodosin.Approved
SiltuximabThe serum concentration of Sildenafil can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Sildenafil.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Sildenafil.Approved
SirolimusThe metabolism of Sirolimus can be decreased when combined with Sildenafil.Approved, Investigational
SitagliptinThe serum concentration of Sildenafil can be increased when it is combined with Sitagliptin.Approved, Investigational
SitaxentanSildenafil may increase the antihypertensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Sildenafil.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Sildenafil.Approved, Investigational
SorafenibThe metabolism of Sorafenib can be decreased when combined with Sildenafil.Approved, Investigational
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Sildenafil.Approved
SpiraprilThe serum concentration of Sildenafil can be increased when it is combined with Spirapril.Approved
St. John's WortThe serum concentration of Sildenafil can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Sildenafil can be increased when it is combined with Stiripentol.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Sildenafil.Approved, Investigational
SulfadiazineThe metabolism of Sildenafil can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Sildenafil.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Sildenafil.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Sildenafil.Approved
SulfisoxazoleThe metabolism of Sildenafil can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Sildenafil.Approved, Investigational
SuprofenThe metabolism of Suprofen can be decreased when combined with Sildenafil.Approved, Withdrawn
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Sildenafil.Approved
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Sildenafil.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Sildenafil.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Sildenafil.Approved, Investigational
TadalafilThe risk or severity of adverse effects can be increased when Sildenafil is combined with Tadalafil.Approved, Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Sildenafil.Approved
TamsulosinSildenafil may increase the hypotensive activities of Tamsulosin.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Sildenafil.Approved
TasosartanThe metabolism of Tasosartan can be decreased when combined with Sildenafil.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Sildenafil.Experimental
TelaprevirThe serum concentration of Sildenafil can be increased when it is combined with Telaprevir.Approved
TelithromycinThe serum concentration of Sildenafil can be increased when it is combined with Telithromycin.Approved
TelmisartanSildenafil may increase the antihypertensive activities of Telmisartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Sildenafil.Approved
TemocaprilThe serum concentration of Sildenafil can be increased when it is combined with Temocapril.Experimental, Investigational
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Sildenafil.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Sildenafil.Approved
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Sildenafil.Approved
TerazosinSildenafil may increase the hypotensive activities of Terazosin.Approved
TerbinafineThe metabolism of Sildenafil can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Sildenafil.Withdrawn
TerlipressinSildenafil may increase the antihypertensive activities of Terlipressin.Approved, Investigational
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Sildenafil.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Sildenafil.Approved, Investigational
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Sildenafil.Approved, Vet Approved
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Sildenafil.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Sildenafil.Approved
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Sildenafil.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Sildenafil.Approved
ThiorphanThe serum concentration of Sildenafil can be increased when it is combined with Thiorphan.Experimental
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Sildenafil.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Sildenafil.Approved
TiboloneSildenafil may increase the antihypertensive activities of Tibolone.Approved
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Sildenafil.Approved
TiclopidineThe metabolism of Sildenafil can be decreased when combined with Ticlopidine.Approved
TicrynafenSildenafil may increase the antihypertensive activities of Ticrynafen.Withdrawn
TimololSildenafil may increase the antihypertensive activities of Timolol.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Sildenafil.Approved, Investigational
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Sildenafil.Approved
TipranavirThe serum concentration of Sildenafil can be increased when it is combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Sildenafil can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Sildenafil.Approved, Investigational
TolazolineSildenafil may increase the antihypertensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Sildenafil can be decreased when combined with Tolbutamide.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Sildenafil.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Sildenafil.Approved
TopiramateThe metabolism of Sildenafil can be decreased when combined with Topiramate.Approved
TorasemideSildenafil may increase the antihypertensive activities of Torasemide.Approved
ToremifeneThe metabolism of Toremifene can be decreased when combined with Sildenafil.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Sildenafil.Approved, Investigational
TramadolThe metabolism of Tramadol can be decreased when combined with Sildenafil.Approved, Investigational
TrandolaprilThe serum concentration of Sildenafil can be increased when it is combined with Trandolapril.Approved
TranylcypromineThe metabolism of Sildenafil can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Sildenafil.Approved
TravoprostSildenafil may increase the antihypertensive activities of Travoprost.Approved
TrazodoneThe metabolism of Trazodone can be decreased when combined with Sildenafil.Approved, Investigational
TreprostinilSildenafil may increase the antihypertensive activities of Treprostinil.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Sildenafil.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Sildenafil.Approved, Vet Approved
TriazolamThe metabolism of Triazolam can be decreased when combined with Sildenafil.Approved
TrichlormethiazideSildenafil may increase the antihypertensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinSildenafil may increase the hypotensive activities of Trimazosin.Experimental
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Sildenafil.Approved
TrimethaphanSildenafil may increase the antihypertensive activities of Trimethaphan.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Sildenafil.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Sildenafil.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Sildenafil.Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Sildenafil.Approved
UbenimexThe serum concentration of Sildenafil can be increased when it is combined with Ubenimex.Experimental
UdenafilThe risk or severity of adverse effects can be increased when Sildenafil is combined with Udenafil.Approved, Investigational
UlinastatinThe serum concentration of Sildenafil can be increased when it is combined with Ulinastatin.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Sildenafil.Approved
UnoprostoneSildenafil may increase the antihypertensive activities of Unoprostone.Approved
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Sildenafil.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Sildenafil.Approved, Investigational
ValsartanSildenafil may increase the antihypertensive activities of Valsartan.Approved, Investigational
VandetanibThe metabolism of Vandetanib can be decreased when combined with Sildenafil.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Sildenafil.Investigational
VardenafilThe risk or severity of adverse effects can be increased when Sildenafil is combined with Vardenafil.Approved
VemurafenibThe metabolism of Vemurafenib can be decreased when combined with Sildenafil.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Sildenafil.Approved
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Sildenafil.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Sildenafil.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Sildenafil.Investigational
VilanterolThe metabolism of Vilanterol can be decreased when combined with Sildenafil.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Sildenafil.Approved
VildagliptinThe serum concentration of Sildenafil can be increased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe metabolism of Vinblastine can be decreased when combined with Sildenafil.Approved
VincristineThe metabolism of Vincristine can be decreased when combined with Sildenafil.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Sildenafil.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Sildenafil.Approved, Investigational
VinpocetineSildenafil may increase the antihypertensive activities of Vinpocetine.Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Sildenafil.Approved
VoriconazoleThe serum concentration of Sildenafil can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Sildenafil.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Sildenafil.Approved
XimelagatranThe serum concentration of Sildenafil can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylometazolineSildenafil may increase the antihypertensive activities of Xylometazoline.Approved
Ym150The serum concentration of Sildenafil can be increased when it is combined with Ym150.Investigational
YohimbineThe metabolism of Yohimbine can be decreased when combined with Sildenafil.Approved, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Sildenafil.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Sildenafil.Approved
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Sildenafil.Approved, Illicit, Investigational
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Sildenafil.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Sildenafil.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Sildenafil.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Sildenafil can be decreased when combined with Ziprasidone.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Sildenafil.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Sildenafil.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Sildenafil.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Sildenafil.Approved
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Sildenafil.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Peter James Dunn, Albert Shaw Wood, “Process for preparing sildenafil.” U.S. Patent US5955611, issued December, 1994.

US5955611
General References
  1. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C: Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 1996 Jun;8(2):47-52. [PubMed:8858389 ]
  2. Cheitlin MD, Hutter AM Jr, Brindis RG, Ganz P, Kaul S, Russell RO Jr, Zusman RM: ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol. 1999 Jan;33(1):273-82. [PubMed:9935041 ]
  3. Fries R, Shariat K, von Wilmowsky H, Bohm M: Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation. 2005 Nov 8;112(19):2980-5. [PubMed:16275885 ]
External Links
ATC CodesG04BE03
AHFS Codes
  • 24:12.12
PDB EntriesNot Available
FDA labelDownload (80.5 KB)
MSDSDownload (37.1 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.6461
Caco-2 permeable+0.7078
P-glycoprotein substrateSubstrate0.7753
P-glycoprotein inhibitor IInhibitor0.672
P-glycoprotein inhibitor IIInhibitor0.8877
Renal organic cation transporterNon-inhibitor0.648
CYP450 2C9 substrateNon-substrate0.6553
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7254
CYP450 1A2 substrateNon-inhibitor0.823
CYP450 2C9 inhibitorInhibitor0.6864
CYP450 2D6 inhibitorNon-inhibitor0.8394
CYP450 2C19 inhibitorNon-inhibitor0.8222
CYP450 3A4 inhibitorInhibitor0.849
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5839
Ames testNon AMES toxic0.5683
CarcinogenicityNon-carcinogens0.6658
BiodegradationNot ready biodegradable0.7641
Rat acute toxicity2.6730 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8664
hERG inhibition (predictor II)Inhibitor0.7602
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
Packagers
Dosage forms
FormRouteStrength
TabletOral25 mg
TabletOral100.0 mg
TabletOral25.0 mg
TabletOral50.0 mg
Injection, solutionIntravenous.8 mg/mL
Injection, solutionIntravenous0.8 mg/ml
Powder, for suspensionOral10 mg/mL
SolutionIntravenous0.8 mg
TabletOral20 mg
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral20 mg
Injection, solutionIntravenous10 mg/12.5mL
TabletOral20 mg/1
Tablet, film coatedOral100 mg
Tablet, film coatedOral25 mg
Tablet, film coatedOral50 mg
TabletOral100 mg
TabletOral50 mg
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral25 mg/1
Tablet, film coatedOral50 mg/1
Tablet, orally disintegratingOral50 mg
Tablet, orally disintegratingOral100 mg
Tablet, orally disintegratingOral25 mg
Prices
Unit descriptionCostUnit
Sildenafil citrate powder24.38USD g
Viagra 50 mg tablet19.45USD tablet
Viagra 100 mg tablet19.45USD tablet
Viagra 25 mg tablet19.45USD tablet
Revatio 20 mg tablet17.5USD tablet
Revatio 10 mg/12.5 ml vial9.33USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2044748 No1998-02-032011-06-17Canada
CA2324324 No2005-12-202020-10-26Canada
US5250534 No1995-03-272012-03-27Us
US6469012 Yes2000-04-222020-04-22Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point189-190 °CNot Available
water solubility3.5 mg/mLNot Available
logP1.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.433 mg/mLALOGPS
logP2.35ALOGPS
logP1.65ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)7.27ChemAxon
pKa (Strongest Basic)5.97ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area109.13 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity139.44 m3·mol-1ChemAxon
Polarizability51.18 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-004i-0002900000-b281f59f40caaba85ac9View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-004i-4436900000-0c5804e76b9d495c76d6View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-0459-6292000000-5a32bfcdda2067978be9View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-00di-0001900000-51b4957d0b3d25c41773View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-01vk-0302900000-86c63c2fd17f7c5b7d6fView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-03dj-8916100000-e941afc576d544ed32a7View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzenesulfonamides
Direct ParentBenzenesulfonamides
Alternative Parents
Substituents
  • Benzenesulfonamide
  • Pyrazolopyrimidine
  • Phenol ether
  • N-alkylpiperazine
  • N-methylpiperazine
  • Pyrimidone
  • Alkyl aryl ether
  • Pyrimidine
  • Piperazine
  • 1,4-diazinane
  • Heteroaromatic compound
  • Vinylogous amide
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Pyrazole
  • Azole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. This phosphodiesterase catalyzes the specific hydrolysis of cGMP to 5'-GMP (PubMed:9714779, PubMed:15489334). Specifically regulates nitric-oxide-generated cGMP (PubMed:15489334).
Gene Name:
PDE5A
Uniprot ID:
O76074
Molecular Weight:
99984.14 Da
References
  1. Carson CC: Long-term use of sildenafil. Expert Opin Pharmacother. 2003 Mar;4(3):397-405. [PubMed:12614192 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. Corbin JD, Francis SH, Webb DJ: Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology. 2002 Sep;60(2 Suppl 2):4-11. [PubMed:12414329 ]
  4. Kruuse C, Thomsen LL, Birk S, Olesen J: Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain. 2003 Jan;126(Pt 1):241-7. [PubMed:12477710 ]
  5. Rybalkin SD, Rybalkina IG, Shimizu-Albergine M, Tang XB, Beavo JA: PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO J. 2003 Feb 3;22(3):469-78. [PubMed:12554648 ]
  6. Wang H, Liu Y, Huai Q, Cai J, Zoraghi R, Francis SH, Corbin JD, Robinson H, Xin Z, Lin G, Ke H: Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development. J Biol Chem. 2006 Jul 28;281(30):21469-79. Epub 2006 May 30. [PubMed:16735511 ]
  7. Wang H, Ye M, Robinson H, Francis SH, Ke H: Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil. Mol Pharmacol. 2008 Jan;73(1):104-10. Epub 2007 Oct 24. [PubMed:17959709 ]
  8. Wang J, Re J, Wang Z: [Mode of action of sildenafil]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1999 Dec;21(6):493-6. [PubMed:12567500 ]
  9. Zoraghi R, Francis SH, Corbin JD: Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors. Biochemistry. 2007 Nov 27;46(47):13554-63. Epub 2007 Nov 3. [PubMed:17979301 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
inhibitor
General Function:
Enzyme inhibitor activity
Specific Function:
Participates in processes of transmission and amplification of the visual signal. cGMP-PDEs are the effector molecules in G-protein-mediated phototransduction in vertebrate rods and cones.
Gene Name:
PDE6G
Uniprot ID:
P18545
Molecular Weight:
9643.09 Da
References
  1. Uckert S, Hedlund P, Andersson KE, Truss MC, Jonas U, Stief CG: Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. Eur Urol. 2006 Dec;50(6):1194-207; discussion 1207. Epub 2006 Jun 6. [PubMed:16815627 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
inhibitor
General Function:
Enzyme inhibitor activity
Specific Function:
Participates in processes of transmission and amplification of the visual signal. cGMP-PDEs are the effector molecules in G-protein-mediated phototransduction in vertebrate rods and cones.
Gene Name:
PDE6H
Uniprot ID:
Q13956
Molecular Weight:
9074.36 Da
References
  1. Uckert S, Hedlund P, Andersson KE, Truss MC, Jonas U, Stief CG: Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. Eur Urol. 2006 Dec;50(6):1194-207; discussion 1207. Epub 2006 Jun 6. [PubMed:16815627 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Ku HY, Ahn HJ, Seo KA, Kim H, Oh M, Bae SK, Shin JG, Shon JH, Liu KH: The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos. 2008 Jun;36(6):986-90. doi: 10.1124/dmd.107.020099. Epub 2008 Feb 28. [PubMed:18308836 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Hyland R, Roe EG, Jones BC, Smith DA: Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br J Clin Pharmacol. 2001 Mar;51(3):239-48. [PubMed:11298070 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Ku HY, Ahn HJ, Seo KA, Kim H, Oh M, Bae SK, Shin JG, Shon JH, Liu KH: The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos. 2008 Jun;36(6):986-90. doi: 10.1124/dmd.107.020099. Epub 2008 Feb 28. [PubMed:18308836 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Hyland R, Roe EG, Jones BC, Smith DA: Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br J Clin Pharmacol. 2001 Mar;51(3):239-48. [PubMed:11298070 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
May be an organic anion pump relevant to cellular detoxification.
Gene Name:
ABCC4
Uniprot ID:
O15439
Molecular Weight:
149525.33 Da
References
  1. Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, Kruh GD: Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50. [PubMed:12036927 ]
  2. Reid G, Wielinga P, Zelcer N, De Haas M, Van Deemter L, Wijnholds J, Balzarini J, Borst P: Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol. 2003 May;63(5):1094-103. [PubMed:12695538 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Acts as a multispecific organic anion pump which can transport nucleotide analogs.
Gene Name:
ABCC5
Uniprot ID:
O15440
Molecular Weight:
160658.8 Da
References
  1. Jedlitschky G, Burchell B, Keppler D: The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem. 2000 Sep 29;275(39):30069-74. [PubMed:10893247 ]
  2. Reid G, Wielinga P, Zelcer N, De Haas M, Van Deemter L, Wijnholds J, Balzarini J, Borst P: Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol. 2003 May;63(5):1094-103. [PubMed:12695538 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
ATP-dependent transporter probably involved in cellular detoxification through lipophilic anion extrusion.
Gene Name:
ABCC10
Uniprot ID:
Q5T3U5
Molecular Weight:
161627.375 Da
References
  1. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD: Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003 Feb;63(2):351-8. [PubMed:12527806 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 03:54